Thermo Fisher Scientific, Inc. (TMO) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (reve...
Thermo Fisher Scientific, Inc.'s revenue increased 3.9% year over year, from $42.88B to $44.56B.
Net income increased 5.8% over the same period, from $6.33B to $6.70B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 144% in total.
Total debt increased by 25.9% to $39.38B.
The debt-to-equity ratio stands at 0.74, indicating a moderate leverage profile.
Operating cash flow declined 9.8% to $7.82B.
Thermo Fisher Scientific, Inc. maintains a healthy net profit margin of 15.0%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $10.60B+0.5% | $1.63B | $4.33B | $1.84B | $2.17B | $100.36B | $35.31B | $48.99B |
| Q4 FY2024 | $11.39B+7.5% | $1.83B | $4.82B | $2.02B | $3.29B | $97.32B | $31.27B | $49.58B |
| Q1 FY2025 | $10.36B-9.0% | $1.51B | $4.24B | $1.72B | $723.0M | $99.04B | $34.19B | $49.39B |
| Q2 FY2025 | $10.86B+4.7% | $1.62B | $4.41B | $1.83B | $1.40B | $101.23B | $35.23B | $50.51B |
| Q3 FY2025 | $11.12B+2.5% | $1.62B | $4.58B | $1.94B | $2.24B | $103.02B | $35.68B | $51.02B |
| Q4 FY2025 | $12.21B+9.8% | $1.96B | $5.01B | $2.25B | $3.46B | $110.34B | $39.38B | $53.41B |
| Q1 FY2026 | $11.01B-9.9% | $1.65B | $4.43B | $1.86B | $1.19B | N/A | N/A | N/A |
| Q2 FY2026 | $11.99B+9.0% | $1.74B | $4.88B | $2.09B | $2.13B | N/A | N/A | N/A |
Balance Sheet Summary (FY2025)
Thermo Fisher Scientific, Inc. (TMO) Financial Statements & Revenue History
Thermo Fisher Scientific, Inc. (TMO) is a US-listed stock operating in the Healthcare sector, specifically the Diagnostics & Research industry trading at $690.49 with a market capitalization of $255. This page provides 42 historical financial statements for Thermo Fisher Scientific, Inc., including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Thermo Fisher Scientific, Inc. reported revenue of $44.6 billion, representing 3.9% year-over-year growth. The net profit margin of 15.0% reflects strong profitability. The debt-to-equity ratio of 0.74 reflects moderate leverage.
TMO Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Thermo Fisher Scientific, Inc.'s revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether TMO is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track TMO's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Thermo Fisher Scientific, Inc. converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of TMO's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use TMO Financial Data
Investors use Thermo Fisher Scientific, Inc.'s financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare TMO's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how TMO's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View TMO's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Thermo Fisher Scientific, Inc.'s SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.TMO trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.